Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in st-segment-elevation acute myocardial infarction the horizons-ami trial

Circulation: Cardiovascular Interventions

Volumn 6, Issue 5, 2013, Pages 518-526

  Palmerini, Tullio ^a   Brener, Sorin J ^b   Mehran, Roxana ^c   Dangas, George ^c   Genereux, Philippe ^d,e,f   Riva, Diego Della ^a   Mariani, Andrea ^a   Xu, Ke ^d,e   Stone, Gregg W ^d,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NEW YORK METHODIST HOSPITAL   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d Department of Medicine   (United States)

^e CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Bivalirudin; Myocardial infarction; Stent

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

BIVALIRUDIN; MYOCARDIAL INFARCTION; STENT;

ACUTE DISEASE; AGED; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; INTEGRIN BETA3; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 84892162254     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.000592     Document Type: Article

References (13)

1. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230
2. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein 2b/3a inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-2204
3. Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K, Brodie B, Lansky A, Stone GW. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction trial. Circulation. 2011;123:2829-2837, 7 p following 2837
4. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008;156:44-56
5. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: A case for tandardized definitions. Circulation. 2007;115:2344-2351
6. Hochholzer W, Wiviott SD, Antman EM, Contant CF, Guo J, Giugliano RP, Dalby AJ, Montalescot G, Braunwald E. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011;123:2681-2689
7. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011;58:1750-1756
8. Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, Steinhubl SR, Smyth SS. Effects of unfractionated heparin and glycoprotein 2b/3a antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007;27:1850-1856
9. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res. 2006;118:361-369
10. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Lösche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets. 2002;13:401- 406
11. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis. 2005;16:401-405
12. Welsby IJ, Jones WL, Arepally G, De Lange F, Yoshitani K, Phillips-Bute B, Grocott HP, Becker R, Mackensen GB. Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. Anesthesiology. 2007;106:295-301
13. Busch G, Steppich B, Sibbing D, Braun SL, Stein A, Groha P, Schömig A, Kastrati A, von Beckerath N, Ott I. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost. 2009;101:340-344